HomeAbout Investor AwarenessClient ServicesClient Success StoriesManagement TeamClient ProfilesContact Us

Client Profiles


Cleveland BioLabsCleveland BioLabs
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. CBLIís programs are focused on the use of novel toll-like receptor agonists to activate the immune system for therapeutic benefit. The Company's most advanced product candidate is entolimod, which is being developed as a radiation countermeasure and an immunotherapy for oncology and other indications. The company maintains strategic relationships with the Cleveland Clinic and Roswell Park Cancer Institute.

CBLI is focused on achieving two major objectives:

  1. Commercializing entolimod as a medical radiation countermeasure through pre-Emergency Use Authorization.
  2. Achieving clinical validation and partnerships for cancer immunotherapies and vaccine adjuvant technology.
Yahoo Data and NewsCompany Web Site

Yahoo Data and News
 Yahoo Finance Data & News
Company Profile Company Profile (PDF)
Company Web Site Company Web Site

News and Updates

StockNewsNow.com Publishes SNNLive Video Interview Update with Pressure BioSciences, Inc.

LOS ANGELES, CA--(November 23, 2015) - StockNewsNow.com, The Official MicroCap News Sourceô, today published an SNNLive Video Interview with Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc. (PBIO), a life sciences company that develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market, according to the Company's website (see here: www.PressureBioSciences.com). The video interview was recorded at the SeeThruEquity MicroCap Investor Forum on November 12th, 2015 in New York City, NY.

(full story)

Pressure BioSciences, Inc. Reports Record Third Quarter and Year-to-Date 2015 Financial Results

SOUTH EASTON, Mass., Nov. 12, 2015 -- Pressure BioSciences, Inc. (PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry, today announced financial results for the three and nine-month periods ended September 30, 2015.

(full story)

Estill, SC Joins Sparta Commercialís Municipal Lease Program

New York, NY.  October 8, 2015 - - Sparta Commercial Services, Inc. (OTCQB: SRCO) announced today that Estill, SC, with a transaction to acquire new Dodge Charger police vehicles to replace older models for its police department, is now the nineteenth and most recent jurisdiction in the Carolinas to choose Sparta's Municipal Lease Program to meet its essential equipment needs.

(full story)

More Articles

Upcoming Events

There are no events to display at this time.
Complete Events List

CorbusCorbus Pharmaceuticals, Inc.
Corbus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat life threatening ("orphan") inflammatory-fibrotic diseases with clear unmet needs. The Companyís lead product Resunab is a first- in-class oral anti-inflammatory expected to commence Phase-2a clinical trials for the treatment of cystic fibrosis and scleroderma pending FDA approval of IND.

About Resunab™
Resunab is a novel synthetic oral drug with unique anti-inflammatory and anti-fibrotic activity. Pre-clinical and Phase 1 studies have shown Resunab to have an excellent safety profile in humans and promising potency. Resunab binds to the CB2 receptor of immune cells and triggers a process known as "inflammatory resolution", in effect turning chronic inflammation "off."
Yahoo Data and NewsCompany Web Site

Minerco, Inc.Minerco, Inc.
Minerco, Inc. is an emerging growth company specializing in the food and beverage industry. The Company’s subsidiary, Athena Brands, Inc. is a specialty beverage company that develops, produces, markets and distributes a diversified collection of forward-thinking, enhanced and healthful consumer brands.
Yahoo Data and NewsCompany Web Site

Pressure BioSciences, Inc.Pressure BioSciences, Inc.
Pressure BioSciences, Inc. is a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry. The Company develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and forensic applications.
Yahoo Data and NewsCompany Web Site




  Disclaimer     Financial Glossary

©2013 Investor Awareness, Inc. All rights reserved